HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

AbstractPURPOSE:
Clinicopathologic data from a population-based endometrial cancer cohort, unselected for age or family history, were analyzed to determine the optimal scheme for identification of patients with germline mismatch repair (MMR) gene mutations.
PATIENTS AND METHODS:
Endometrial cancers from 702 patients recruited into the Australian National Endometrial Cancer Study (ANECS) were tested for MMR protein expression using immunohistochemistry (IHC) and for MLH1 gene promoter methylation in MLH1-deficient cases. MMR mutation testing was performed on germline DNA of patients with MMR-protein deficient tumors. Prediction of germline mutation status was compared for combinations of tumor characteristics, age at diagnosis, and various clinical criteria (Amsterdam, Bethesda, Society of Gynecologic Oncology, ANECS).
RESULTS:
Tumor MMR-protein deficiency was detected in 170 (24%) of 702 cases. Germline testing of 158 MMR-deficient cases identified 22 truncating mutations (3% of all cases) and four unclassified variants. Tumor MLH1 methylation was detected in 99 (89%) of 111 cases demonstrating MLH1/PMS2 IHC loss; all were germline MLH1 mutation negative. A combination of MMR IHC plus MLH1 methylation testing in women younger than 60 years of age at diagnosis provided the highest positive predictive value for the identification of mutation carriers at 46% versus ≤ 41% for any other criteria considered.
CONCLUSION:
Population-level identification of patients with MMR mutation-positive endometrial cancer is optimized by stepwise testing for tumor MMR IHC loss in patients younger than 60 years, tumor MLH1 methylation in individuals with MLH1 IHC loss, and germline mutations in patients exhibiting loss of MSH6, MSH2, or PMS2 or loss of MLH1/PMS2 with absence of MLH1 methylation.
AuthorsDaniel D Buchanan, Yen Y Tan, Michael D Walsh, Mark Clendenning, Alexander M Metcalf, Kaltin Ferguson, Sven T Arnold, Bryony A Thompson, Felicity A Lose, Michael T Parsons, Rhiannon J Walters, Sally-Ann Pearson, Margaret Cummings, Martin K Oehler, Penelope B Blomfield, Michael A Quinn, Judy A Kirk, Colin J Stewart, Andreas Obermair, Joanne P Young, Penelope M Webb, Amanda B Spurdle
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 32 Issue 2 Pg. 90-100 (Jan 10 2014) ISSN: 1527-7755 [Electronic] United States
PMID24323032 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Adaptor Proteins, Signal Transducing
  • DNA-Binding Proteins
  • G-T mismatch-binding protein
  • MLH1 protein, human
  • Nuclear Proteins
  • Adenosine Triphosphatases
  • PMS2 protein, human
  • MSH2 protein, human
  • Mismatch Repair Endonuclease PMS2
  • MutL Protein Homolog 1
  • MutS Homolog 2 Protein
  • DNA Repair Enzymes
Topics
  • Adaptor Proteins, Signal Transducing (genetics, metabolism)
  • Adenosine Triphosphatases (genetics, metabolism)
  • Adult
  • Aged
  • Aged, 80 and over
  • Australia
  • Cohort Studies
  • DNA Methylation
  • DNA Mismatch Repair (genetics)
  • DNA Repair Enzymes (genetics, metabolism)
  • DNA-Binding Proteins (genetics, metabolism)
  • Early Detection of Cancer (methods)
  • Endometrial Neoplasms (diagnosis, genetics, metabolism)
  • Female
  • Genetic Testing (methods)
  • Germ-Line Mutation
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Mismatch Repair Endonuclease PMS2
  • MutL Protein Homolog 1
  • MutS Homolog 2 Protein (genetics, metabolism)
  • Nuclear Proteins (genetics, metabolism)
  • Population Surveillance (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: